Clinical trials: Dissection of Aorta, Thoracic
Breast Cancer, Lung Cancer
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
The purpose of this study is to test the combination of an experimental drug known as MGCD0103 given along with an FDA-approved drug called docetaxel.
- Conditions
- Breast Cancer, Lung Cancer, Pulmonary Cancer, Non-Small-Cell Lung Carcinoma
- Trial name
- NCT00511576
- Testing
- MGCD0103 & Docetaxel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Mirati Therapeutics Inc.
Advanced/Recurrent Non-small-cell Lung Cancer
A Study of ARQ 197 in Combination With Erlotinib
This is a phase I study to determine the safety, tolerability and recommended phase II dose of ARQ 197 given in combination with erlotinib as primary endpoints in CYP2C19 poor metabolizer patients with advanced/recurrent…
- Trial name
- NCT01251796
- Testing
- ARQ 197 and Erlotinib
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
NSCLC
Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC
A prospective, single-arm, non-randomized, multi-center, open-label study following patients with resectable stage IIB to IIIA non-small cell lung cancer after Pulsed Electric Fields (PEF) ablation who may be candidates for…
- Trial name
- VIGOR (NCT05583188)
- Testing
- Aliya Pulsed Electric Fields (PEF) ablation, Nivolumab plus Platinum Doublet Chemotherapy, Standard of care neoadjuvant therapy
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Galvanize Therapeutics, Inc.
Neoplasms, Carcinoma, Non-Small-Cell Lung
Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC
Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.
- Trial name
- NCT02824094
- Testing
- crizotinib
- Where
- 4 sites in Japan
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement [N2])…
- Trial name
- INTerpath-002 (NCT06077760)
- Testing
- Intismeran autogene, Pembrolizumab
- Where
- 229 sites in United States, Argentina and 31 more
- Volunteers
- 868 people
- Sponsor
- Merck Sharp & Dohme LLC
Aneurysm Thoracic, Dissection of Aorta, Thoracic
TBE Zone 2 PMS in Japan
The goal of this surveillance is to confirm the TBE device's safety and efficacy in patients treated with proximal landing in Zone 2 in the post-marketing period.
- Conditions
- Aneurysm Thoracic, Dissection of Aorta, Thoracic, Trauma
- Trial name
- NCT07049913
- Testing
- Gore® TAG® Thoracic Aortic Branch Stent Graft System
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- W.L.Gore & Associates
Non Small Cell Lung Cancer
A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC
This is an open-label, fixed-sequence Phase I clinical study that evaluates the effect of multiple doses of aumolertinib on the pharmacokinetics of midazolam (CYP 3A4 probe substrate) in sensitive EGFR (Epidermal Growth Factor…
- Trial name
- NCT06926413
- Testing
- Aumolertinib；midazolam
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Neoplasms
A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is effective in the treatment of advanced stage…
- Trial name
- NCT00074854
- Testing
- CP-547,632
- Where
- 20 sites in United States
- Volunteers
- 87 people
- Sponsor
- Pfizer
Small Cell Lung Cancer
A Study of Bevacizumab in Previously Untreated Extensive-Stage Small Cell Lung Cancer (SALUTE)
This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin (or carboplatin) and etoposide in patients with previously…
- Trial name
- NCT00403403
- Testing
- Bevacizumab, Chemotherapy
- Volunteers
- 102 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours
A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor…
- Trial name
- AURA2 (NCT02094261)
- Testing
- AZD9291
- Where
- 44 sites in United States, Canada and 6 more
- Volunteers
- 210 people
- Sponsor
- AstraZeneca
Colorectal Cancer, Non-small Cell Lung Cancer
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
- Conditions
- Colorectal Cancer, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02538627
- Testing
- MM-151, MM-121, MM-141
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Merrimack Pharmaceuticals
Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
To evaluate the tolerability and safety of axalimogene filolisbac 1 x 10^10 colony forming units (cfu) administered with prophylactic premedication in repeating 3-dose study cycles in women with persistent, metastatic, or…
- Conditions
- Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer, Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma
- Trial name
- NCT02164461
- Testing
- Axalimogene filolisbac
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Advaxis, Inc.
Advanced NSCLC
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
This study is researching an experimental drug called REGN5093-M114 by itself and in combination with cemiplimab. The study is focused on advanced non-small cell lung cancer (NSCLC) that produces too much of a protein called…
- Trial name
- NCT04982224
- Testing
- REGN5093-M114, Cemiplimab
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Regeneron Pharmaceuticals
Lung Cancer
Clinical Investigation Evaluating the Performance, Safety and Clinical Benefit of the Endowave FlexAblate™ Microwave Ablation System in Patients Undergoing Lung Ablation Procedures.
The goal of this clinical trial is to learn if the FlexAblate™ Ablation System works to treat a lung cancer nodules and it will also learn about the safety of the ablation system.
- Trial name
- AURORA (NCT07291973)
- Testing
- Microwave Ablation
- Where
- 3 sites in France, United Kingdom
- Volunteers
- 43 people
- Sponsor
- Endowave Ltd.
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
Carcinoma, Non-small-Cell Lung
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in…
- Trial name
- PALOMA-2 (NCT05498428)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 110 sites in United States, Brazil and 10 more
- Volunteers
- 520 people
- Sponsor
- Janssen Research & Development, LLC
Non-Small Cell Lung Cancer Stage III
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
This is a randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of CS1001 in subjects with locally advanced/unresectable (Stage III) non-small cell lung cancer that has not…
- Trial name
- NCT03728556
- Testing
- CS1001 monoclonal antibody
- Where
- China
- Volunteers
- 381 people
- Sponsor
- CStone Pharmaceuticals
Solid Tumor
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
In phase Ia study, the safety and tolerability of SI-B003 in patients with recurrent or metastatic solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum…
- Trial name
- NCT04606472
- Testing
- SI-B003
- Where
- 8 sites in China
- Volunteers
- 60 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.